The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

On completion of docetaxel chemotherapy, patients at the Rosemere Cancer Centre (Preston, UK) are closely monitored every 4–6 weeks ... the potential to extend survival, but there is no evidence ...

As 2025 dawns, here is a look at some of the storylines that could shape the fate of tropical forests this year. More reading ...

CES 2025 is here with mind-bending tech, AI-driven innovations and futuristic gadgets to groundbreaking advancements in ...

We expect the series to become a window through which more foreign readers will understand how Chinese people recognize human ...

In 2024, we’ve witnessed some incredible advancements in medicine, from gene editing to stem cell therapies. These ...

Assad, the wife of former Syrian President Bashar al-Assad, is reportedly fighting leukemia, a serious blood cancer. She is ...